5,7-Dihydroxy-2-(4-hydroxyphenyl)chroman-4-one
Common Name: |
5,7-Dihydroxy-2-(4-hydroxyphenyl)chroman-4-one |
IUPAC Name: |
5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one |
Molecular Formula: |
C15H12O5 |
SMILES: |
C1C(OC2=CC(=CC(=C2C1=O)O)O)C3=CC=C(C=C3)O |
Inchi: |
1S/C15H12O5/c16-9-3-1-8(2-4-9)13-7-12(19)15-11(18)5-10(17)6-14(15)20-13/h1-6,13,16-18H,7H2 |
Inchi Key: |
FTVWIRXFELQLPI-UHFFFAOYSA-N |
Cas No: |
67604-48-2 |
Name |
Value |
Lipinski Violations |
0 |
Ghose Violations |
0 |
Veber Violations |
0 |
Egan Violations |
0 |
Muegge Violations |
0 |
Name |
Value |
Molecular Weight (g/mol) |
272.25 |
Mass (g/mol) |
272.068 |
Molar Refractivity |
71.57 |
Net Charge |
-1 |
HBD |
3 |
HBA |
5 |
Rt Bonds |
1 |
Rings |
3 |
TPSA |
86.99 |
Hetero Atoms |
5 |
Heavy Atoms |
20 |
Aromatic Heavy Atoms |
12 |
Melting Point (°C) |
251 |
Boiling Point (°C@760.00mm Hg) |
577.5 |
Vapor Pressure (mmHg@25.00 °C) |
|
Vapor Density (Air =1) |
|
Fraction Csp3 |
0.13 |
LogP |
2.51 |
iLOGP |
1.75 |
XLOGP3 |
2.52 |
WLOGP |
2.19 |
MLOGP |
0.71 |
ESOL Log S |
-3.49 |
ESOL Solubility (mg/ml) |
0.087 |
ESOL Solubility (mol/l) |
0 |
ESOL Class: esol_class |
Soluble |
Ali Log S |
-3.99 |
Ali Solubility (mg/ml) |
0.03 |
Ali Solubility (mol/l) |
0 |
Ali Class |
Soluble |
Silicos-IT LogSw |
-3.42 |
Silicos-IT Solubility (mg/ml) |
0.1 |
Silicos-IT Solubility (mol/l) |
0 |
Silicos-IT Class |
Soluble |
Name |
Value |
GI Absorption |
High |
BBB Permeable |
0 |
PgP Substrate |
1 |
Log Kp (cm/s) |
-6.17 |
Bioavailability Score |
0.55 |
Caco2 |
1 |
Human Intestinal Absorption |
1 |
Plasm Protein Binding |
1.001 |
CYP1A2 Inhibitor |
1 |
CYP2C19 Inhibitor |
0 |
CYP2C9 Inhibitor |
0 |
CYP2D6 inhibitor |
0 |
CYP3A4 inhibitor |
1 |
Ames mutagenesis |
0 |
Acute Oral Toxicity |
1.87 |
Carcinogenicity (Binary) |
0 |
Carcinogenicity (Trinary) |
Non-required |
Eye Irritation |
1 |
Hepatotoxicity |
1 |
Androgen Receptor Binding |
1 |
Aromatase Binding |
1 |
Estrogen Receptor Binding |
1 |
Glucocorticoid Receptor Binding |
1 |
Thyroid Receptor Binding |
1 |
BRCP inhibitor |
1 |
BSEP inhibitor |
0 |
OATP1B1 inhibitor |
1 |
OATP1B3 inhibitor |
1 |
OATP2B1 inhibitor |
0 |
OCT1 inhibitor |
0 |
OCT2 inhibitor |
0 |